Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.58 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130240 | 0.80 | HDAC1 (0.60) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL4115137 | 0.75 | HDAC1 (0.44) | HDAC1HDAC3HDAC2HDAC8HDAC10 | |
| SCHEMBL4131217 | 0.75 | HDAC1 (0.59) | HDAC1HDAC3HDAC2HDAC8HDAC10 | |
| SCHEMBL13965318 | 0.75 | HDAC1 (0.59) | HDAC1HDAC3HDAC2HDAC8HDAC10 | |
| SCHEMBL4921109 | 0.74 | HDAC3 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL3997411 | 0.73 | HDAC1 (0.43) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL2243090 | 0.72 | ALDH1A1 (0.64) | MEN1KMT2AALDH1A1LMNAFAAH | |
| SCHEMBL13965309 | 0.72 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL6485095 | 0.72 | ALDH1A1 (0.64) | MEN1KMT2AALDH1A1LMNAFAAH | |
| SCHEMBL4916851 | 0.72 | HDAC1 (0.78) | HDAC1HDAC3HDAC2HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694329-A4 | DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATES | ATON PHARMA INC (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090023718-A1 | Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives | ATON PHARMA, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023718-A1 | Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives | ATON PHARMA, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023718-A1 | Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives | ATON PHARMA, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1694329-A2 | DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATES | Aton Pharma, Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005053610-A2 | DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATIVES | ATON PHARMA, INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005053610-A2 | DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATIVES | ATON PHARMA, INC. (US) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023718-A1 | Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives | AADAC, BRDT, HDAC5 | HDAC1 5/4885HDAC3 15/4885HDAC2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.